研究领域

分子生物学，生物化学

论文与著作

1. Wang C, LuoY, Tang H, Yan Y, Chang X, Zhao R, Li Q, Yang P, Hong B, Xu Y, Huang Q^*, Liu J^*. Hsa_circ_0031608:A Potential Modulator of VSMC Phenotype in the Rupture of Intracranial Aneurysms. Frontiers in Molecular Neuroscience. 2022, doi:10.3389/fnmol.2022.842865.

2. Luo Y, Yang Y, HouW^*, Fu J^*. Novel Algicides against Bloom-FormingCyanobacteria from Allelochemicals: Design, Synthesis, Bioassay, and 3D-QSARStudy. Biology. 2021, 10, 1145.

3. Luo Y, Tang H,Zhang Z, Zhao R, Hou W^*, Huang Q, LiuJ^*. Pharmacological inhibition of epidermal growth factor receptor attenuates intracranial aneurysm formation by modulating the phenotype of vascular smooth muscle cells. CNSNeuroscience & Therapeutics. 2022, 28, 64-76.

4. Luo Y, Wang Y, FuJ^*. Nanomaterials in Cerebro vascular Disease Diagnose and Treatment. Particle & Particle SystemsCharacterization. 2021, 38, 2000311.

5. Li H^†, Luo Y^†, LiuP, Liu P, Hua W, Zhang Y, Zhang L, Li Z, Xing P, Zhang Y, Hong B, Yang P^*, Liu J^*.Exosomes containingmiR-451a is involved in the protective effect of cerebral ischemicpreconditioning against cerebral ischemia and reperfusion injury. CNS Neuroscience & Therapeutics. 2021, 27,564-576.

6. Li H^†, Luo Y^†, Zhu L, Hua W, Zhang Y, Zhang H, Zhang L, Li Z, Xing P, Zhang Y, Hong B,Yang P^*,Liu J^*. Glia-derivedexosomes: Promising therapeutic targets. Life Sciences. 2019, 239,116951.

7. Tang H^†, Luo Y^†, Zuo Q^†, Wang C,Huang Q, Zhao R^*, Liu J^*. Current Understanding of the Molecular Mechanismbetween Hemodynamic-Induced Intracranial Aneurysm and Inflammation. CurrentProtein and Peptide Science. 2019, 20, 1-10.

8. Chen G,Luo Y, Warncke K, Sun Y, Yu D, Fu H, Behera M, Ramalingam S, Doetsch P, Lammers M,Curran W, Deng X^*. Acetylationregulates ribonucleotide reductase activity and cancer cell growth. Nature Communications. 2019, 10, Article number: 3213.

9. Li H^†, Luo Y^†, Yang P^*, Liu J^*. Hydrogen as a complementary therapy against ischemic stroke: Areview of the evidence. Journal of the NeurologicalSciences. 2019, 396, 240-246.

10. Luo Y^†,*, Tang H^†, Li H^†, Zhao R, Huang Q^*, Liu J^*. Recent advances in the development of neuroprotective agents and therapeutictargets in the treatment of cerebral ischemia. Eur. J. Med. Chem. 2019, 162,132-146

11. 李翯，骆银，杨鹏飞，刘建民. 缺血性脑卒中神经保护治疗的研究进展. 第二军医大学学报，2018, 39,1040-1046.

12. Luo Y^†, Zhou Y^†, Song Y, ChenG, Wang Y. X., Tian Y, Fan W. W., Yang Y. S., Cheng T, Zhu H. L^*. Optimization of Substituted Cinnamic Acyl Sulfonamide Derivatives as Tubulin Polymerization Inhibitors with Anticancer Activity. Bioorg. Chem. Lett, 2018, DOI: 10.1016/j.bmcl.2018.10.037.

13. Mo XL, Luo Y, Ivanov AA, Su R, Havel JJ, Li Z, Khuri F, Du Y^*, Fu H^*. Enabling systematic interrogation of protein-protein inter actions in live cells with a versatile ultra-high-throughput biosensor platform. J. Mol. Cell Bio. 2016, 8, 271-281.

14. Luo Y^†, Liu Z. J.^†, Shi J, Li J. R., Zhu H. L.^* 1,3,4-Oxadiazole derivatives as potential antitumoragents: discovery, optimization and biological activity evaluation. Med.Chem. Commun., 2016, 7(2),263-271.

15. Zhou Y^†, Luo Y^†, Yang Y. S., Lu L, Zhu H. L.^* Study of acylhydrazone derivatives with deoxygenated seven-membered ringsas potential beta-ketoacyl-acyl carrier protein synthase III (FabH) inhibitors.Med.Chem. Commun., 2016, 7(10), 1980-1987.

16. Luo Y.^†, Zhou Y.^†, Fu J., Zhu H. L.^*4,5-Dihydropyrazole derivatives containing oxygen-bearing heterocycles aspotential telomerase inhibitors with anticancer activity. RSC ADVANCES, 2014, 4(45), 23904-23913.

17. Zhang S^†., Luo Y^†., He  L. Q., Liu Z. J., Jiang A. Q., Yang Y. H., ZhuH. L.^* Synthesis,biological evaluation, and molecular docking studies of novel 1,3,4-oxadiazolederivatives possessing benzotriazole moiety as FAK inhibitors with anticanceractivity. Bioorganic & Medicinal Chemistry,2013,21, 3723-3729.

18. Luo Y.^†, Zhang S.^†, Liu Z. J., Fu J.^* Synthesis and antimicrobical evalution of a novel class of 1,3,4-thiadiazole: derivatives bearing 1,2,4-triazolo[1,5-a] pyrimidine moiety.European Journal of Medicinal Chemistry, 2013, 64, 54-61.

19. Luo Y.^†, Zhang S.^†, Qiu K. M., Zhu H. L.^* Synthesis, biological evaluation, 3D-QSAR studies of novel aryl-2H-pyrazolederivatives as telomerase inhibitors.Bioorganic & Medicinal Chemistry Letter,2013, 23, 1091-1095.

20. Luo Y. ^†, Yang Y. S. ^†, Fu J., ZhuH. L.^* Novel FabH inhibitors:a patent and article literature review (2000-2012). Expert Opinion on Therapeutic Patents, 2012, 22，1325-1336.

21. Luo Y. ^†, Zhang L. R.^†, Hu Y.,Zhang S., Fu J., Wang X. M., Zhu H. L.^* Synthesis and Antimicrobial Activities of OximesDerived from O-Benzylhydroxylamine as FabH Inhibitors. ChemMedChem, 2012, 7, 1587 -1593.

22. Li Y^†.,Luo Y^†., Hu Y., Zhu D.D., Zhang S., Liu Z. J., Gong H. B., Zhu H. L.^* Design, synthesis and antimicrobial activities ofnitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors.Bioorganic & Medicinal Chemistry,2012, 20, 4316-4322.

23. Luo Y. ^†, Song R. ^†, Li Y., ZhangS., Liu Z. J., Fu J., Zhu H. L.^* Design,synthesis, and biological evaluation of chalcone oxime derivatives as potentialimmunosuppressive agents. Bioorganic & Medicinal Chemistry Letters, 2012, 22, 3039-3043.

24. Li H. Q., Luo Y., Qiao C. H. The Mechanisms ofAnticancer Agents by Genistein and Synthetic Derivatives of Isoflavone. Mini-Reviews in Medicinal Chemistry,2012, 12, 350-362.

25. Luo Y., Li Y., Qiu K. M., Lu X., Fu J., Zhu H. L.Metronidazole acid acyl sulfonamide: A novel class of anticancer agents andpotential EGFR tyrosine kinase inhibitors.Bioorganic & Medicinal Chemistry, 2011, 19, 6069-6076.

26. Luo Y., Qiu K. M., Lu X., Liu K., Fu J., Zhu H. L.Synthesis, biological evaluation, and molecular modeling of cinnamic acylsulfonamide derivatives as novel antitubulin agents. Bioorganic & Medicinal Chemistry, 2011, 19, 4730-4738.

27. Li H. Q., Luo Y., Zhu H. L. Discovery ofvinylogous carbamates as a novel class of β-ketoacyl-acyl carrier protein synthaseIII (FabH) inhibitors. Bioorganic &Medicinal Chemistry, 2011, 19, 4454-4459.

28. Luo Y., Li H. Q., Zhou Y., Li Z. L., Yan T., Zhu H. L.Metronidazole-Deoxybenzoin Derivatives as Anti-Helicobacter pylori Agents with Potent Inhibitory Activity againstHPE-Induced Interleukin-8. ChemMedChem,2010, 5, 1110 -1116.

29. Li H. Q.^†, Luo Y. ^†, SongR., Li Z. L., Yan T., Zhu H. L. Design, Synthesis, and ImmunosuppressiveActivity of New Deoxybenzoin Derivatives. ChemMedChem,2010, 5, 1117-1122.

30. 朱海亮,骆银,李环球.一种肟类化合物及其制备方法与用途，专利号：ZL 200910233389.3.

31. 朱海亮,仇晓阳,李耀,骆银,刘芝珺. 一种查耳酮肟类化合物作为新型免疫抑制剂的制备方法与用途.专利号：ZL 201110351329.9.

32. 朱海亮,骆银,王宇翔,田野,范未伟.一种含氧杂环的磺胺类衍生物在抗癌药物中的应用.专利号：ZL 201210122265.X.

33. 朱海亮,李耀,骆银.恶二唑衍生物的合成及其在抗菌药物方面的应用.申请号：201210098367.2.

34. 朱海亮,李耀,骆银.硝基咪唑衍生物的合成及其在抗菌药物方面的应用.申请号：201210098359.8.

35. 朱海亮,张帅,骆银.一类含苯并三氮唑结构的1,3,4-恶二唑衍生物的制法与用途.申请号：201210499005.4.

36. 张洪剑,杨鹏飞,赵瑞,骆银,赵普远,王川川,李嘉楠,冯明陶,唐海双.模拟血管壁受力作用的transwell细胞培养装置. 专利号：ZL 201810206947.6.

37. 陈果,骆银.一种MCL-1抑制剂及其制备方法与应用.申请号：202011503260.2.

 荣誉与奖励

1. 2023年，湖北省“楚天学者”。

2. 2023年，湖北省青年拔尖人才。

3. 2018年获长海医院“先进工作者”称号

4. 2013年获 南京大学“优秀毕业生”称号

5. 2012年获南京大学研究生国家奖学金

6. 2012年获南京大学优秀研究生奖学金

7. 2011年获南京大学赵安中奖学金

8. 2011年获 南京大学“优秀研究生”称号

9. 2010年获南京大学潘雪平助学金

10. 2009年获南京大学“化学生物学与药物设计”暑期学校学员一等奖

11. 2009年获南京大学优秀研究生奖学金

12. 2004年-2008年获南京大学西部开发助学工程奖